Year: 2022
Type: review
Abstract: The number of patients with hearing loss is on the rise due to congenital abnormalities, degenerative changes in old age, and acquired injuries such as virus or ototoxic drug-induced diseases. Hearing loss is a refractory and disabling disease that has serious negative effects on quality of life. The pathology of hearing loss in the inner ear is characterized by varying degrees of damage to the cochlear sensory epithelium cells (such as hair cells and supporting cells), stria vascularis (including marginal, intermediate and basal cells) and spiral ganglion neurons. Regeneration or direct repair of damaged cells in the inner ear is an effective way to treat sensorineural deafness. It is currently possible to regenerate hair cells to treat sensorineural hearing loss by FX-322, a small molecule drug in clinical trials. With the development of genetic engineering technology, gene therapy has brought a promising treatment strategy for many previously intractable diseases. Gene therapy has been regarded as a promising method in the treatment and rehabilitation of sensorineural hearing loss, and recombinant adeno-associated virus gene therapy has been widely used in fundamental research into hearing loss treatments. At present, gene therapy for hearing loss is transitioning from feasibility studies to explorations of its safety and its therapeutic potential. The present article reviews the concepts, strategies, and applications of gene therapy mediated by recombinant adeno-associated viruses in the field of hearing loss treatment.
Source: Fundamental Research
Institutions: Beijing Institute of Technology, Zhongda Hospital Southeast University, Aerospace Center Hospital, State Key Laboratory of Digital Medical Engineering, Southeast University, Zhongnan Hospital of Wuhan University, Shandong Provincial Hospital, Shandong First Medical University, University of Electronic Science and Technology of China, Capital Medical University, Chinese Academy of Sciences, Nantong University, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Language: English
Subfield: Sensory Systems
Field: Neuroscience
Domain: Life Sciences
Open Access status: diamond
Funders: National Natural Science Foundation of China, Chinese Academy of Sciences, China Postdoctoral Science Foundation, Government of Jiangsu Province, Fudan University, Natural Science Foundation of Jiangsu Province, Department of Science and Technology of Sichuan Province, State Key Laboratory of Genetic Engineering, Shenzhen Fundamental Research Program, National Postdoctoral Program for Innovative Talents, National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities, Thousand Young Talents Program of China
Awards: G1011270330, G1144520724, G1880609003, G2083639890, G2296957957, G262236214, G288145952, G3308117525, G3426172395, G4210868709, G4832002281, G5037361530, G5417391657, G5591760066, G6004314494, G6630886690, G6911272103, G6971596443, G6983853783, G715276135, G7640387804, G7814624945, G7891576750, G8030255855, G8388929666, G960661552
OpenAlex ID: W4294884772